AUSTIN, TX / ACCESSWIRE / September 11, 2020 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that it will present at the HC Wainwright & Co. Global Investment Conference on Tuesday, September 15 at 3:00 PM Eastern Time. Todd Newton, CEO, and Stefanie Cavanaugh, CFO, will be presenting and available for one-on-one investor meetings.
Institutional and other qualified investors may request one-on-one meetings via HC Wainwright & Co. if they have an existing relationship, or by contacting Apollo 's investor relations, Matt Kreps of Darrow Associates, at [email protected].
About Apollo Endosurgery, Inc.
Apollo Endosurgery, Inc. is a medical technology company focused on less invasive therapies to treat various gastrointestinal conditions, ranging from gastrointestinal complications to the treatment of obesity. Apollo's device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 75 countries today and include the OverStitch™ Endoscopic Suturing System, the OverStitch Sx™ Endoscopic Suturing System, and the ORBERA® Intragastric Balloon.
Apollo's common stock is traded on the Nasdaq Global Market under the symbol "APEN". For more information regarding Apollo Endosurgery, go to: www.apolloendo.com.
Apollo Endosurgery, Inc.
Stefanie Cavanaugh, 512-279-5100
Darrow Associates Investor Relations
Matt Kreps, 214-597-8200
SOURCE: Apollo Endosurgery, Inc.